Physician profile
Arthur Maydell
NPI 1992078745
$1,767.21
in general payments reported to CMS, 2019-2025
13 companies · $627 in 2025
The $627 reported for 2025 was more than what a typical Vascular & Interventional Radiology provider received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $114 · 2021: $36.87 · 2022: $87.26 · 2023: $280 · 2024: $360 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,267.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,019.60 | 2019-2025 | General - Embolics, General - Vascular Intervention, Rubicon 18 |
| Penumbra, INC. | $200.14 | 2024-2025 | Indigo System |
| Tactile Systems Technology INC | $160.78 | 2020-2023 | Flexitouch Plus, Entre Plus |
| Medtronic Vascular, INC. | $85.55 | 2019 | |
| Abbott Laboratories | $78.29 | 2020 | |
| Protega Pharmaceutials INC | $62.24 | 2025 | Roxybond |
| Philips North America LLC | $38.40 | 2019-2020 | |
| Advanced Oxygen Therapy INC. | $25.91 | 2024-2025 | Topical Oxygen Chamber For Extremities |
| Cordis US Corp. | $21.67 | 2025 | |
| Janssen Pharmaceuticals, INC | $20.82 | 2022 | |
| Bard Peripheral Vascular, INC. | $19.76 | 2023 | Venovo |
| Cardiovascular Systems INC. | $18.00 | 2021 | |
| Medtronic, INC. | $16.05 | 2023 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Maydell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.